Switzer TV

 

Welcome back for another year of stock picks, top LICs and trading tips with Switzer Investing TV. Good to have you aboard.

On this kick-off ep for the new year, we're looking at roughed-up companies on the market that might be worth a second look. Quality stocks are being sold hard, resources are back in favour, and investors are asking the same uncomfortable question, is this a buying opportunity or a value trap?

In this first show of the year, Peter Switzer sits down with Adam Dawes from Shaw and Partners, Mike Gable from Fairmont Equities, and Paul Rickard from the Switzer Report to cut through the noise.

They run the ruler over some of the market’s most talked-about names, including CSL, NextDC, Xero, WiseTech, Pro Medicus, lithium plays, uranium stocks, and gold. Fundamentals meet charts, sentiment clashes with valuation, and the panel doesn’t always agree. You’ll hear why great businesses can fall a long way without anything being “wrong”, what the charts are really saying about beaten-up tech, why resources have momentum again, and whether gold is still a defensive play with upside in 2026.

Switzer Investing TV (19/12/25): Are these smashed stocks worth your time?

On this kick-off ep for the new year, we're looking at roughed-up companies on the market that might be worth a second look. Quality stocks are being sold hard, resources are back in favour, and investors are asking the same uncomfortable question, is this a buying opportunity or a value trap?

More videos

Did health authorities make the right decision about COVID-19?

Dr Ross Walker shares his criticisms about how the coronavirus pandemic has been handled.

Series: ,
Time for Gladys to mask up!

Peter Switzer and Paul Rickard discuss masking up for the economy, rising gold prices and the looming reporting season.

Series: ,
Experts give these tech stocks a thumbs up!

On this week's show: Burman Invest's Julia Lee, Medallion's Michael Wayne, Morgans' Michael Knox and Switzer's Paul Rickard.

Series: ,
What therapies are available for COVID-19?

Dr Ross Walker examines the effectiveness of hydroxychloroquine.

Series: ,
Why is the stock market ignoring infections?

Peter Switzer and Paul Rickard discuss gains in the stock market despite infection rates in Victoria and the US, the Aussie dollar moving above 71 US cents and when employees will head back to the office.

Series: ,
Could Afterpay really go to $100? Plus, reliable stocks you can trust!

Joining Peter Switzer on this week's show: Burman Invest's Julia Lee, Shaw and Partners' Adam Dawes, FNArena's Rudi Filapek-Vandyck and Metrics Credit Partners' Andrew Lockhart.

Series: ,
The COVID-19 game-changer

With over 100 vaccines for COVID-19 currently being trialled, Dr Ross Walker explains what vaccination is and how the latest research into Coronavirus vaccines is progressing.

Series: ,
Steven Turner from Rafaella Resources (ASX:RFR)

Peter Switzer is joined by the Managing Director of Rafaella Resources (RFR), Steven Turner.

Series: ,
Super is in shambles!

Peter Switzer and Paul Rickard discuss problems with the compulsory superannuation system, Wall Street madness overnight, the COVID-19 situation in Victoria and what the iron ore price says about the economy.

Series: ,
Switzer does drugs! Coronavirus killers, medicinal cannabis & other drugs!

Julia Lee, James Graham, Rhys Cohen and Paul Rickard join this week's show to discuss investing in the drug space.

Series: ,
Why are there more COVID-19 cases in the northern hemisphere?

Dr Ross Walker explains what kind of people and places are more susceptible to the Coronavirus.

Series: ,
Are Afterpay's founders exiting and should you follow?

Peter Switzer and Paul Rickard discuss the latest news on Afterpay, Victorian Premier Daniel Andrew's handling of COVID-19 and why US share players are ignoring a spike in cases.

Series: ,
1 42 43 44 45 46 51

Fill in the form below to subscribe to Switzer Daily and get our latest articles, videos and podcasts sent straight to your inbox

Get the latest financial, business, and political expert commentary delivered to your inbox.

When you sign up, we will never give away or sell or barter or trade your email address.

And you can unsubscribe at any time!
Subscribe
© 2006-2021 Switzer. All Rights Reserved. Australian Financial Services Licence Number 286531. 
shopping-cartphoneenvelopedollargraduation-cap linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram